Episode 14: A4M Las Vegas: What I Saw, What’s Changing, and What Still Misses the Mark

What happens when you attend the world’s largest anti-aging medicine conference after more than two decades in advanced female hormone medicine? You don’t just hear what’s being taught—you hear what’s still being avoided.

In this episode of the MeNoPause Moxie Podcast, Clinical Hormone Coach Marie Hoäg takes you inside the A4M (American Academy of Anti-Aging Medicine) conference in Las Vegas. Together with co-host Maggie Kuhn, Marie breaks down what stood out, what surprised her, and why longevity medicine continues to fall short when it comes to estrogen, female hormone restoration, and real healthspan for women.

This is not a highlight reel. It’s a clinical, insider analysis of where anti-aging medicine is evolving—and where it remains stuck in low-dose, symptom-management thinking.

In this episode, we cover:

• What A4M is and why it remains the entry point for physicians entering anti-aging and functional medicine
• How female hormone balancing became categorized under “anti-aging” medicine
• The shift in leadership, tone, and energy at A4M over the past two decades
• Why menopause is still framed as something to manage instead of a hormone deficiency to correct
• Key lectures that stood out, including:
• Dr. Erika Schwartz on menopause equity and women’s health
• Dr. Molly Maloof on love, relationships, and cellular health
• Calley Means (HHS) on nutrition, healthcare economics, and systemic reform
• The disconnect between longevity medicine and advanced female hormone restoration
• Why peptides, supplements, diagnostics, and treatments are often used to compensate for underdosed estrogen
• The business model behind symptom management—and why it persists
• What women must understand to protect themselves in today’s confusing hormone landscape

This episode delivers a blunt truth: longevity medicine without estrogen restoration isn’t longevity—it’s symptom management, and women pay the price.